The possible effectiveness of denosumab treatment in MASLD could be hypothesised based on another work (Figure 3): compared to the placebo group, Weivoda et al. observed an improvement in glucagon-like peptide 1 (GLP-1) expression in subjects treated with denosumab [92]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.